Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer

Takeshi Hashimoto, Krishnan Rahul, Toshikazu Takeda, Nicole Benfante, John P. Mulhall, Hedvig Hricak, James A. Eastham, Hebert Alberto Vargas

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective To investigate the multiparametric prostate magnetic resonance imaging (mpMRI) findings in patients treated with testosterone replacement therapy (TRT) while on active surveillance for low-risk prostate cancer. Methods We retrospectively reviewed 12 patients who underwent mpMRI before and after TRT while on active surveillance. Changes in serum testosterone level, prostate-specific antigen (PSA), prostate biopsy findings, prostate volume, and Prostate Imaging Reporting and Data System Version 2 (PI-RADSv2) score before and after TRT were summarized. Results After TRT, there was a significant increase in serum testosterone (516.5 ng/dl vs. 203.0 ng/dl), PSA (4.2 ng/ml vs. 3.3 ng/ml), and prostate volume (55.2 cm3 vs. 39.4 cm3). In total, 2 patients had biopsy progression during the study period. The PI-RADSv2 scores before and after TRT were unchanged in 10/12 patients; none of these demonstrated biopsy progression on post-TRT. The PI-RADSv2 scores increased after TRT in 2/12 patients; both showed Gleason score upgrade on follow-up biopsy. Of these 2 patients, 1 patient underwent radical treatment due to clinical progression. The area under the curve for detecting biopsy progression calculated from PI-RADSv2 score after TRT was 0.90, which was better than that calculated from post-TRT PSA level (0.48). Conclusions After TRT, mpMRI findings remained stable in patients without biopsy progression, whereas PI-RADSv2 score increase was identified in patients with Gleason score upgrade on follow-up biopsy.

Original languageEnglish
Pages (from-to)530.e9-530.e14
JournalUrologic Oncology: Seminars and Original Investigations
Volume34
Issue number12
DOIs
Publication statusPublished - 2016 Dec 1
Externally publishedYes

Fingerprint

Testosterone
Prostate
Prostatic Neoplasms
Magnetic Resonance Imaging
Information Systems
Biopsy
Prostate-Specific Antigen
Therapeutics
Neoplasm Grading
Serum
Area Under Curve

Keywords

  • Active surveillance
  • Multiparametric prostate magnetic resonance imaging
  • Prostate cancer
  • Testosterone deficiency
  • Testosterone replacement therapy

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer. / Hashimoto, Takeshi; Rahul, Krishnan; Takeda, Toshikazu; Benfante, Nicole; Mulhall, John P.; Hricak, Hedvig; Eastham, James A.; Vargas, Hebert Alberto.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 34, No. 12, 01.12.2016, p. 530.e9-530.e14.

Research output: Contribution to journalArticle

Hashimoto, Takeshi ; Rahul, Krishnan ; Takeda, Toshikazu ; Benfante, Nicole ; Mulhall, John P. ; Hricak, Hedvig ; Eastham, James A. ; Vargas, Hebert Alberto. / Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer. In: Urologic Oncology: Seminars and Original Investigations. 2016 ; Vol. 34, No. 12. pp. 530.e9-530.e14.
@article{21942e7fe646483abd8ca0f37439bb8c,
title = "Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer",
abstract = "Objective To investigate the multiparametric prostate magnetic resonance imaging (mpMRI) findings in patients treated with testosterone replacement therapy (TRT) while on active surveillance for low-risk prostate cancer. Methods We retrospectively reviewed 12 patients who underwent mpMRI before and after TRT while on active surveillance. Changes in serum testosterone level, prostate-specific antigen (PSA), prostate biopsy findings, prostate volume, and Prostate Imaging Reporting and Data System Version 2 (PI-RADSv2) score before and after TRT were summarized. Results After TRT, there was a significant increase in serum testosterone (516.5 ng/dl vs. 203.0 ng/dl), PSA (4.2 ng/ml vs. 3.3 ng/ml), and prostate volume (55.2 cm3 vs. 39.4 cm3). In total, 2 patients had biopsy progression during the study period. The PI-RADSv2 scores before and after TRT were unchanged in 10/12 patients; none of these demonstrated biopsy progression on post-TRT. The PI-RADSv2 scores increased after TRT in 2/12 patients; both showed Gleason score upgrade on follow-up biopsy. Of these 2 patients, 1 patient underwent radical treatment due to clinical progression. The area under the curve for detecting biopsy progression calculated from PI-RADSv2 score after TRT was 0.90, which was better than that calculated from post-TRT PSA level (0.48). Conclusions After TRT, mpMRI findings remained stable in patients without biopsy progression, whereas PI-RADSv2 score increase was identified in patients with Gleason score upgrade on follow-up biopsy.",
keywords = "Active surveillance, Multiparametric prostate magnetic resonance imaging, Prostate cancer, Testosterone deficiency, Testosterone replacement therapy",
author = "Takeshi Hashimoto and Krishnan Rahul and Toshikazu Takeda and Nicole Benfante and Mulhall, {John P.} and Hedvig Hricak and Eastham, {James A.} and Vargas, {Hebert Alberto}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.urolonc.2016.07.004",
language = "English",
volume = "34",
pages = "530.e9--530.e14",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer

AU - Hashimoto, Takeshi

AU - Rahul, Krishnan

AU - Takeda, Toshikazu

AU - Benfante, Nicole

AU - Mulhall, John P.

AU - Hricak, Hedvig

AU - Eastham, James A.

AU - Vargas, Hebert Alberto

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Objective To investigate the multiparametric prostate magnetic resonance imaging (mpMRI) findings in patients treated with testosterone replacement therapy (TRT) while on active surveillance for low-risk prostate cancer. Methods We retrospectively reviewed 12 patients who underwent mpMRI before and after TRT while on active surveillance. Changes in serum testosterone level, prostate-specific antigen (PSA), prostate biopsy findings, prostate volume, and Prostate Imaging Reporting and Data System Version 2 (PI-RADSv2) score before and after TRT were summarized. Results After TRT, there was a significant increase in serum testosterone (516.5 ng/dl vs. 203.0 ng/dl), PSA (4.2 ng/ml vs. 3.3 ng/ml), and prostate volume (55.2 cm3 vs. 39.4 cm3). In total, 2 patients had biopsy progression during the study period. The PI-RADSv2 scores before and after TRT were unchanged in 10/12 patients; none of these demonstrated biopsy progression on post-TRT. The PI-RADSv2 scores increased after TRT in 2/12 patients; both showed Gleason score upgrade on follow-up biopsy. Of these 2 patients, 1 patient underwent radical treatment due to clinical progression. The area under the curve for detecting biopsy progression calculated from PI-RADSv2 score after TRT was 0.90, which was better than that calculated from post-TRT PSA level (0.48). Conclusions After TRT, mpMRI findings remained stable in patients without biopsy progression, whereas PI-RADSv2 score increase was identified in patients with Gleason score upgrade on follow-up biopsy.

AB - Objective To investigate the multiparametric prostate magnetic resonance imaging (mpMRI) findings in patients treated with testosterone replacement therapy (TRT) while on active surveillance for low-risk prostate cancer. Methods We retrospectively reviewed 12 patients who underwent mpMRI before and after TRT while on active surveillance. Changes in serum testosterone level, prostate-specific antigen (PSA), prostate biopsy findings, prostate volume, and Prostate Imaging Reporting and Data System Version 2 (PI-RADSv2) score before and after TRT were summarized. Results After TRT, there was a significant increase in serum testosterone (516.5 ng/dl vs. 203.0 ng/dl), PSA (4.2 ng/ml vs. 3.3 ng/ml), and prostate volume (55.2 cm3 vs. 39.4 cm3). In total, 2 patients had biopsy progression during the study period. The PI-RADSv2 scores before and after TRT were unchanged in 10/12 patients; none of these demonstrated biopsy progression on post-TRT. The PI-RADSv2 scores increased after TRT in 2/12 patients; both showed Gleason score upgrade on follow-up biopsy. Of these 2 patients, 1 patient underwent radical treatment due to clinical progression. The area under the curve for detecting biopsy progression calculated from PI-RADSv2 score after TRT was 0.90, which was better than that calculated from post-TRT PSA level (0.48). Conclusions After TRT, mpMRI findings remained stable in patients without biopsy progression, whereas PI-RADSv2 score increase was identified in patients with Gleason score upgrade on follow-up biopsy.

KW - Active surveillance

KW - Multiparametric prostate magnetic resonance imaging

KW - Prostate cancer

KW - Testosterone deficiency

KW - Testosterone replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=84994410090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994410090&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2016.07.004

DO - 10.1016/j.urolonc.2016.07.004

M3 - Article

C2 - 27665357

AN - SCOPUS:84994410090

VL - 34

SP - 530.e9-530.e14

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 12

ER -